Trial Profile
A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pegpleranib (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors IVERIC bio
- 31 Oct 2016 Primary endpoint has been met. (Mean change in visual acuity from baseline at the Week 24 visit), as per OphthoTech Corporation media release.
- 31 Oct 2016 Results published in the journal of the American Academy of Ophthalmology, as per OphthoTech Corporation media release.
- 31 Oct 2016 Results from this trial published online in Ophthalmology, the journal of the American Academy of Ophthalmology, as per OphthoTech Corporation media release.